TOP

TOP Expands into OTC Derivatives Business in Multiple Market

Retrieved on: 
Tuesday, October 25, 2022
Association, Offering, New York Mercantile Exchange, Review, OTC, OSE, NASDAQ, Securities and Futures Commission, Goal, Acquisition, Private Securities Litigation Reform Act, Nasdaq, GLOBE, Hong Kong China Ferry Terminal, Chicago Board of Trade, Hong Kong Futures Exchange, Forward-looking statement, RMB, Technology, Securities Association of China, Osaka Exchange, Company, Dalian Commodity Exchange, CEO, Chicago, SEC, Eurex Exchange, TOP, Singapore Exchange, Security (finance), Chicago Mercantile Exchange, Financial adviser

Hong Kong China, Oct. 25, 2022 (GLOBE NEWSWIRE) --  TOP Financial Group Limited (“TOP” or the "Company") (NASDAQ: TOP), a fast-growing online brokerage firm located in Hong Kong specializing in the trading of local and foreign equities, futures, options products and other financial services, today announced that the company is planning to initiate its over-the-counter (OTC) derivatives business in 2023. In addition to existing exchange traded equities, futures and options, TOP will add the OTC derivatives, which including China A-share, Hong Kong and US stock options.

Key Points: 
  • In addition to existing exchange traded equities, futures and options, TOP will add the OTC derivatives, which including China A-share, Hong Kong and US stock options.
  • Derivatives market presents tremendous opportunity for us.
  • Just China A share market alone, the derivatives products were RMB 2.08 trillion1 (USD 328 billion) in January 2022, and the U.S. derivatives market was RMB several hundred trillion.
  • The major participants in the OTC stock options market include large institutional investors such as mutual funds, commercial banks, pension funds, and funds of funds, and private investors.

EARNPARK LAUNCHES A PLATFORM TO SIMPLIFY AND BOOST PASSIVE INCOME IN CRYPTO

Retrieved on: 
Tuesday, October 25, 2022
Security, APY, Decentralized finance, Sleep, Industry, Digital, TOP, Ministry of National Education (France), Public interest accounting, Cryptocurrency, Financial services, Bank

Earnpark is a crypto investment platform that provides financial services for investors looking to earn interest using cryptocurrencies (digital assets).

Key Points: 
  • Earnpark is a crypto investment platform that provides financial services for investors looking to earn interest using cryptocurrencies (digital assets).
  • Earnpark is incorporated in London, United Kingdom and founded by the team ranking among the TOP 100 qualified liquidity providers for the worlds largest cryptocurrency exchange Binance .
  • The team generates hedged crypto yield through investment strategies for passive income at various user risk profiles.Their plan is to democratize the hedge fund market which is now not available to regular retail investors.
  • Earnpark is a liquidity provider that maximizes profitability by developing, automating, and algorithmizing its own strategies in the CeFi and DeFi markets.

XT.COM Launches Version 4.0 With Latest Updates, Enhanced Features and Brand-New User Experience

Retrieved on: 
Wednesday, October 26, 2022
Metaverse, Web browser, Non-fungible token, XT, FAQ, Efficiency, Social, Transaction, NFT, TOP, Ecosystem, Decentralized finance, UTC, Asset, Online shopping, Cryptocurrency

SINGAPORE, Oct. 25, 2022 /PRNewswire/ -- XT.COM, the world's first socially infused trading platform, has launched version 4.0 for an enhanced user experience.

Key Points: 
  • SINGAPORE, Oct. 25, 2022 /PRNewswire/ -- XT.COM, the world's first socially infused trading platform, has launched version 4.0 for an enhanced user experience.
  • The launch of XT.COM's version 4.0 trading platform marks a milestone in XT.COM's newly improved trading experience.
  • If you own a mobile device with version 3.15.0 and above, you can access the new features on XT.COM's homepage.
  • Enhanced Assets Features: The new Assets page has features that include an overview section of all assets.

Black Adam (Original Motion Picture Soundtrack) by Grammy Award-Winning Composer Lorne Balfe Now Available on WaterTower Music

Retrieved on: 
Friday, October 14, 2022
Music, Film & Motion Pictures, General Entertainment, Entertainment, TV and Radio, Bodhi, DC, Paramount Pictures, WarnerMedia, Cate Shortland, Hope, Jaume Collet-Serra, THE, Orient Express, BAFTA, BLACK, Music, Oscar, Justice, The Orient Express, Warner Bros., A24, Universal, Industry, TOP, Television, Destiny, Warner Bros. Pictures, Albert Rothstein, Paramount, WaterTower Music, Aldis Hodge, LIFE, Boy, BAD, Toy, Film

Refusing to surrender, Teth Adam is challenged by a team of modern day heroes known as the Justice SocietyHawkman, Dr.

Key Points: 
  • Refusing to surrender, Teth Adam is challenged by a team of modern day heroes known as the Justice SocietyHawkman, Dr.
  • New Line Cinema Presents a Seven Bucks/Flynn Picture Co. Production, A Jaume Collet-Serra Film, Black Adam, distributed worldwide by Warner Bros. Pictures.
  • WaterTower Music, the in-house label for the WarnerMedia companies, releases recorded music as rich and diverse as the companies themselves.
  • It has been the soundtrack home to many of the worlds most iconic films, television shows and games since 2001.

EQS-News: splendid medien AG: Splendid Performance in Cinema and Home Entertainment

Retrieved on: 
Thursday, October 13, 2022
Memory, Apple, DVD, De Grote Slijmfilm, TOP, Television, Film

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • In the Netherlands, "MISFIT The Switch", the fifth part of the popular MISFIT series (after three films and one original series), started at the beginning of October.
  • The film unites a new generation of leading actors who, like the previous successful predecessors, are also recruited from well-known and popular Dutch actors and influencers.
  • The German theatrical release is planned for December 29, 2022.

Hugel resubmits BLA for its botulinum toxin, Botulax to the U.S. FDA

Retrieved on: 
Saturday, October 8, 2022
CRL, Allergan, BLESS, Endpoint security, Marketing, TOP, KRW, CEO, BLA, FDA, Dietary supplement, Pharmaceutical industry, Hugel & Fils

Hugel had received a Complete Response Letter (CRL) from the U.S. FDA last March after submitting the BLA for Botulax (50 and 100 units) in order to advance into the U.S. market in March of last year.

Key Points: 
  • Hugel had received a Complete Response Letter (CRL) from the U.S. FDA last March after submitting the BLA for Botulax (50 and 100 units) in order to advance into the U.S. market in March of last year.
  • The company sent supplemental documents and data based on requests set out in the CRL and resubmitted the BLA to the U.S. FDA.
  • Hugel America, a U.S. subsidiary which will be in charge of Hugel's U.S. sales and marketing of Botulax.
  • It submitted a BLA in April of last year, and undertook on-site due diligence at its Geodu factory in August.

Hugel resubmits BLA for its botulinum toxin, Botulax to the U.S. FDA

Retrieved on: 
Friday, October 7, 2022
CRL, Allergan, BLESS, Endpoint security, Marketing, TOP, KRW, CEO, BLA, FDA, Dietary supplement, Pharmaceutical industry, Hugel & Fils

Hugel had received a Complete Response Letter (CRL) from the U.S. FDA last March after submitting the BLA for Botulax (50 and 100 units) in order to advance into the U.S. market in March of last year.

Key Points: 
  • Hugel had received a Complete Response Letter (CRL) from the U.S. FDA last March after submitting the BLA for Botulax (50 and 100 units) in order to advance into the U.S. market in March of last year.
  • The company sent supplemental documents and data based on requests set out in the CRL and resubmitted the BLA to the U.S. FDA.
  • Hugel America, a U.S. subsidiary which will be in charge of Hugel's U.S. sales and marketing of Botulax.
  • It submitted a BLA in April of last year, and undertook on-site due diligence at its Geodu factory in August.

Hugel resubmits BLA for its botulinum toxin, Botulax to the U.S. FDA

Retrieved on: 
Friday, October 7, 2022
CRL, Allergan, BLESS, Endpoint security, Multimedia, Marketing, TOP, KRW, CEO, BLA, FDA, View, Dietary supplement, Pharmaceutical industry, Hugel & Fils

SEOUL, South Korea, Oct. 7, 2022 /PRNewswire/ -- Hugel (CEO Jihoon Sohn), a global total medical aesthetics company, announced that it resubmitted the BLA for its botulinum toxin called Botulax on October 6th (local time), for the indication of glabellar lines to the U.S. FDA.

Key Points: 
  • SEOUL, South Korea, Oct. 7, 2022 /PRNewswire/ -- Hugel (CEO Jihoon Sohn), a global total medical aesthetics company, announced that it resubmitted the BLA for its botulinum toxin called Botulax on October 6th (local time), for the indication of glabellar lines to the U.S. FDA.
  • Hugel had received a Complete Response Letter (CRL) from the U.S. FDA last March after submitting the BLA for Botulax (50 and 100 units) in order to advance into the U.S. market in March of last year.
  • The company sent supplemental documents and data based on requests set out in the CRL and resubmitted the BLA to the U.S. FDA.
  • Hugel America, a U.S. subsidiary which will be in charge of Hugel's U.S. sales and marketing of Botulax.

Hugel resubmits BLA for its botulinum toxin, Botulax to the U.S. FDA

Retrieved on: 
Friday, October 7, 2022
CRL, Allergan, BLESS, Endpoint security, Multimedia, Marketing, TOP, KRW, CEO, BLA, FDA, View, Dietary supplement, Pharmaceutical industry, Hugel & Fils

SEOUL, South Korea, Oct. 7, 2022 /PRNewswire/ -- Hugel (CEO Jihoon Sohn), a global total medical aesthetics company, announced that it resubmitted the BLA for its botulinum toxin called Botulax on October 6th (local time), for the indication of glabellar lines to the U.S. FDA.

Key Points: 
  • SEOUL, South Korea, Oct. 7, 2022 /PRNewswire/ -- Hugel (CEO Jihoon Sohn), a global total medical aesthetics company, announced that it resubmitted the BLA for its botulinum toxin called Botulax on October 6th (local time), for the indication of glabellar lines to the U.S. FDA.
  • Hugel had received a Complete Response Letter (CRL) from the U.S. FDA last March after submitting the BLA for Botulax (50 and 100 units) in order to advance into the U.S. market in March of last year.
  • The company sent supplemental documents and data based on requests set out in the CRL and resubmitted the BLA to the U.S. FDA.
  • Hugel America, a U.S. subsidiary which will be in charge of Hugel's U.S. sales and marketing of Botulax.

Valbiotis Accelerates Its Marketing Strategy

Retrieved on: 
Friday, October 7, 2022
Biotechnology, Pharmaceutical, Health, Cardiology, Union, AMF, Risk, Development, AEC, ERDF, Growth, European Regional Development Fund, Pharmacy, NAFL, Lists of diseases, Research and development, Patient, Investor, LDL, Cropping system, Research, TOTUM, Blood pressure, PEA, Partnership, NASH, IFREMER, Company, Marketing, Pathology, TOP, IFOP, Prediabetes, BPI, Medicine, Pharmacist, Degenerative disease, DNA, Heart, Practitioner, Solution, Pharmaceutical industry, Dietary supplement, Aquaculture

Valbiotis (FR0013254851 ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, is accelerating its marketing strategy.

Key Points: 
  • Valbiotis (FR0013254851 ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, is accelerating its marketing strategy.
  • At the same time, consumers/patients will be targeted directly through an adapted digital marketing strategy.
  • For more information about Valbiotis, please visit: www.valbiotis.com
    This press release contains forward-looking statements about Valbiotis objectives.
  • Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time.